Methotrexate in psoriatic polyarthritis

P. D. Pigatto, E. Gibelli, R. Ranza, A. Rossetti

Research output: Contribution to journalArticlepeer-review


Methotrexate (MTX) is widely accepted as an effective treatment for psoriasis and chronic polyarthrides. We report data from 54 psoriatic polyarthritis patients (354 encounters) treated with MTX. 65% were males, mean age 47.9 years, mean disease duration 9.8 years for arthritis, 14.2 years for psoriasis. The MTX dose was 10-12.5 mg/week. 32 patients are still on MTX after a mean treatment time of 1.6 years. 22 patients discontinued MTX treatment: 11 felt it to be ineffictive, in 6 patients there were side effects, 3 patients obtained remission, while 2 patients underwent surgery. Efficacy was good on the whole: number of swollen and tender joints, global disease activity score, ESR, and CRP all underwent a significant reduction. The intake of symptomatic drugs was reduced in 40%. Psoriasis as assessed with the Psoriasis Activity and Severity Index showed a significant improvement. Our data confirm that MTX is of value in most psoriatic polyarthritis patients (60%). In our experience, this drug, gives the maximum efficacy within 6 months of therapy.

Original languageEnglish
Pages (from-to)114-115
Number of pages2
JournalActa Dermato-Venereologica, Supplement
Issue number186
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Methotrexate in psoriatic polyarthritis'. Together they form a unique fingerprint.

Cite this